Sangamo Biosciences's total assets for Q3 2025 were $88.64M, a decrease of -9.14% from the previous quarter. SGMO total liabilities were $82.40M for the fiscal quarter, a 5.70% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.